Vaccine-elicited V3 loop-specific antibodies in rhesus monkeys and control of a simian-human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate envelope

Journal of Virology

Volumn 75, Issue 9, 2001, Pages 4165-4175

  Letvin, N L ^a   Robinson, S ^a   Rohne, D ^a   Axthelm, M K ^a   Fanton, J W ^a   Bilska, M ^a   Palker, T J ^a   Liao, H X ^a   Haynes, B F ^a   Montefiori, D C ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; HUMAN IMMUNODEFICIENCY VIRUS 1; MONKEY DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; RHESUS MONKEY; SIMIAN IMMUNODEFICIENCY VIRUS; T LYMPHOCYTE SUBPOPULATION; VIREMIA; VIRUS ENVELOPE; VIRUS INFECTION; VIRUS ISOLATION; VIRUS REPLICATION;

AIDS VACCINES; AMINO ACID SEQUENCE; ANIMALS; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; MACACA MULATTA; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; PEPTIDE FRAGMENTS; PEPTIDES; SIMIAN IMMUNODEFICIENCY VIRUS; T-LYMPHOCYTES, CYTOTOXIC; VACCINATION; VACCINES, SYNTHETIC;

EID: 0035043246     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.75.9.4165-4175.2001     Document Type: Article

References (45)

1. Neutralization of primary and T-cell line adapted isolates of human immunodeficiency virus type 1: Role of V3-specific antibodies
2. Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization
3. Immunization with recombinant canarypox vectors expressing membrane-anchored gp120 followed by gp160 protein boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1
4. A vaccine for HIV type 1: The antibody perspective
5. Serotyping of HIV-1 infections: Definition, relationship to viral genetic sub-types, and assay evaluation
6. The β-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates
7. The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-mediated blockade of infection
8. Characterization of primary isolate-like variants of simian-human immunodeficiency virus
9. High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates
10. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody
11. Characterization of simian-human immunodeficiency virus envelope glycoprotein epitopes recognized by neutralizing antibodies from infected macaques
12. Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus
13. Infection of HTL V-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay
14. Induction of HIVMN neutralizing antibodies in primates using a prime-boost regimen of hybrid synthetic gp120 envelope peptides
15. Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein
16. + T cells and AIDS in pig-tailed macaques
17. Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination
18. Induction of antibodies in guinea pigs and rhesus monkeys against the human immunodeficiency virus type 1 envelope: Neutralization of nonpathogenic and pathogenic primary isolate simian/human immunodeficiency virus strains
19. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies
20. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies
21. Mechanism of human immunodeficiency virus type 1 (HIV-1) neutralization: Irreversible inactivation of infectivity by anti-HIV-1 antibody
22. Evidence that antibody-mediated neutralization of human immunodeficiency virus type 1 is independent of coreceptor usage
23. Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors
24. Neutralizing antibodies in sera from macaques infected with chimeric simian-human immunodeficiency virus containing the envelope glycoproteins of either a laboratory-adapted variant or a primary isolate of human immunodeficiency virus type 1
25. Evaluation of antiviral drugs and neutralizing antibodies to human immunodeficiency virus by a rapid and sensitive microtiter infection assay
26. Type-specific neutralization of the human immunodeficiency virus with antibodies to envencoded synthetic peptides
27. Polyvalent human immunodeficiency virus synthetic immunogen comprised of envelope gp120 T helper cell sites and B cell neutralization epitopes
28. A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys
29. An env gene derived from a primary human immunodeficiency virus type 1 isolate confers high in vivo replicative capacity to a chimeric simian/human immunodeficiency virus in rhesus monkeys
30. Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations
31. Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope gp120
32. A region of the third variable loop of HIV-1 gp120 is recognized by HLA-B7-restricted CTLs from two acute seropositive patients
33. Gene regulating HLA class I antigen expression in T-B lymphoblast hybrids
34. Characterization of the specificity of the human antibody response to the V3 neutralization domain of HIV-1
35. Imunization with a modified vaccinia virus expressing simian immunodeficiency virus (SIV) Gag-Pol primes for an anamnestic Gag-specific cytotoxic T-lymphocyte response and is associated with reduction of viremia after SIV challenge
36. Study of the V3 loop as a target epitope for antibodies involved in the neutralization of primary isolates versus T-cell-line-adapted strains of human immunodeficiency virus type 1
37. HxB
38. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5
39. + target cells is a major mechanism of T cell line-adapted HIV-1 neutralization
40. Neutralizing antibodies against the V3 loop of human immunodeficiency virus type 1 gp120 block the CD4-dependent and -independent binding of virus to cells
41. Differential role of V3-specific antibodies in neutralization assays involving primary and laboratory-adapted isolates of HIV type 1
42. The majority of neutralizing abs in HIV-1-infected patients recognize linear V3 loop sequences. Studies using HIV-1 MN multiple antigenic peptides
43. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5
44. Antibody-mediated neutralization of primary isolates of human immunodeficiency virus type 1 in peripheral blood mononuclear cells is not affected by the initial activation state of the cells
45. Frequent and early HIV-1 MN neutralizing capacity in sera from Dutch HIV-1 seroconverters is related to antibody reactivity to peptides from gp120 V3 domain